摘要
目的:研究血必净注射液对危重病患者可溶性髓系细胞表达的触发受体(sTREM)-1与白细胞介素(IL)-6、IL-10的影响。方法:将入住我院重症加强治疗病房(ICU)的危重病患者46例随机分为常规组22例与血必净组24例,在相同的常规治疗基础上,血必净组加用血必净注射液100mL静脉滴注,每天2次,连续7d。2组患者治疗前与治疗后第3、7天,进行急性生理学与慢性健康状况(APACHEⅡ)评分,分别采血检测sTREM-1、IL-6、IL-10的水平,记录28d死亡率。结果:与治疗前比较,治疗后血必净组患者体内sTREM-1、IL-6、IL-6/IL-10水平显著降低;治疗后第3天、第7天血必净组sTREM-1、IL-6、IL-6/IL-10水平均显著低于常规组(P<0.01或P<0.05),28d死亡率显著低于常规组(P<0.05)。治疗后第7天血必净组APACHEⅡ评分较常规组显著降低(P<0.05)。结论:血必净注射液能明显降低体内TREM-1、IL-6、IL-6/IL-10的水平,减轻全身炎症反应,改善预后。
OBJECTIVE: To investigate the effects of Xuebijing injection on sTREM-1, IL-6 and IL-10 in critical patients. METHODS: 46 patients, admitted to intensive care unit (ICU) were randomly divided into the routine group (n=22) and Xuebi- jing group (n=24). Xuebijing group was given Xuebijing injection 100 mL twice daily for 7 days besides routine therapy. Serum concentrations of sTREM-1, IL-6, IL-10 and APACHE Ⅱ scores were determined before and 3 days and 7 days after administration. The mortality was calculated in 28 days. RESULTS: Compared with therapy, the concentrations of serum sTREM-1, IL-6, IL-6/ IL-10 were significantly lowered in Xuebijing grotip after treatment. Those of Xuebijing group were significantly lower than routine group on 3rd day and ?th day after treatment (P〈0.01 or P〈0.05). The ratio of 28-day mortality in Xuebijing group was signifi- cantly lower than routine group (P〈0.05). APACHE Ⅱ scores of Xuebijing group were obviously lower than those of routine group on 7th day after treatment (P〈0.05).CONCLUSION:Xuebijing injection can significantly decrease serum sTREM-1 IL-6 and IL-6/ IL-10 concentrations, alleviate inflammatory response and improve clinical outcome.
出处
《中国药房》
CAS
CSCD
2012年第27期2568-2570,共3页
China Pharmacy
基金
无锡市卫生系统中医药指导性科研项目(ZZD0803)